01/14/2026
ODG by MCG Director of Product Management, Pamela Bloom-Pugliese, RN, BSN, MBA, and Associate Vice President for Strategic Solutions & Regulatory Affairs, Troy J. Prevot MBA PA-C ATC, have published a new white paper that discusses why anchoring and decisions in evidence-based medicine improves safety, consistency, and defensibility—while still allowing to add meaningful value. As organizations increasingly use analytics to forecast risk and prioritize interventions, relying solely on historical claims data can unintentionally reinforce bias and non-clinical influences. For this reason, evidence-based medicine (EBM) and diagnosis-specific disability duration guidelines must come first. You can download the white paper here: https://info.mcg.com/odg-white-paper-evidence-first.html?utm_medium=social&utm_source=facebook&utm_campaign=odg-wc&utm_content=wp-odg-evidence-first